How does Tremfya work to treat plaque psoriasis and psoriatic arthritis?
Medically reviewed by Judith Stewart, BPharm. Last updated on Jul 15, 2020.
Tremfya (guselkumab) is a biologic therapy that selectively blocks interleukin 23 (IL-23), a pro-inflammatory cytokine thought to play a major role in chronic immune-mediated diseases, including plaque psoriasis and psoriatic arthritis.
Tremfya is a fully human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. By blocking interleukin 23, Tremfya inhibits the release of cytokines and chemokines that cause inflammation.
Tremfya is an interleukin-23 blocker indicated for the treatment of adult patients with:
- moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
- active psoriatic arthritis.
Tremfya was the first interleukin-23 blocker to be approved for the treatment of plaque psoriasis, and the first interleukin-23 blocker to be approved for psoriatic arthritis.
See Tremfya Approval History.
FDA Approved Interleukin-23 Blockers
|Brand||Generic Name||FDA Approval||Indications|
Related Medical Questions
- Halobetasol vs. clobetasol - how do they compare?
- What is a substitute for fluocinonide cream?
- How long after stopping methotrexate will it be completely out of my system?
- What are the new drugs for the treatment of plaque psoriasis?
- Is fluocinonide an antifungal cream?
- How do you use clobetasol propionate on your scalp?
- What is fluocinonide cream good for?